Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation

The article presents data on the efficacy of erlotinib in the treatment of NSCLC in the presence of EGFR gene mutation. Its advantages over chemotherapy in terms of survival, quality of life, and tolerability of treatment, both as monotherapy and in combination with cytostatics and other targeted dr...

Description complète

Détails bibliographiques

Auteurs principaux:	S. V. Orlov, A. M. Lozhkina, S. V. Odintsova, M. A. Sviridenko, A. O. Cheremnykh, M. A. Urtenova, E. A. Filippova
Format:	Artigo
Langue:	Russo
Publié:	Remedium Group LLC 2019-06-01
Collection:	Медицинский совет
Sujets:	lung cancer egfr mutations erlotinib
Accès en ligne:	https://www.med-sovet.pro/jour/article/view/3054
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!